Akeso to Present at Citi 2024 Global Healthcare Conference and the 7th Annual Evercore HealthCONx Conference

PR Newswire21:23 ET

Hong Kong Stock Announcement Gold Mining | Bosideng (03998) announces mid-term performance, the profit attributable to equity shareholders rose by 23% year-on-year to approximately 1.13 billion yuan.

Dianzhi (02586) will conduct IPO from November 28th to December 3rd, planning to globally issue 25.774 million shares; Reshaping Energy (02570) will conduct IPO from November 28th to December 3rd, planning to globally issue approximately 4.8279 million shares.

Zhitong FinanceNov 28 10:16 ET

Akeso's Cervical Cancer Drug Included in China's National Reimbursement Drug List

MT NewswiresNov 28 04:29 ET

Akeso's Carfilzomib and Ivoysna are included in the national medical insurance catalogue for 2024.

Hong Kong, November 28, 2024 /PR Newswire/ -- On November 28, Akeso (9926.HK) announced that two independently developed globally innovative bispecific antibody drugs -- Kantanz (Cadonilimab injection, PD-1/CTLA-4 bispecific) and Yidafang (Ivosidenib injection, PD-1/VEGF bispecific) have been included in the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2024)" ("National Medical Insurance Catalog", which will be officially implemented from January 1, 2025). Akeso's founder, director, chairman, and president.

PR NewswireNov 28 02:06 ET

Express News | Akeso - Inclusion in China's National Reimbursement Drug List of Cadonilimab and Ivonescimab

ReutersNov 27 23:05 ET

[Brokerage Focus] Bocom Intl: Inflection point of the pharmaceutical sector has arrived in 2025, focusing on innovation and fundamental recovery.

Kingwo Financial News | bocom intl states that the turning point for the pharmaceutical global sectors has arrived, with two main lines to focus on in 2025: the pharmaceutical sector ended years of underperformance against the large cap in the second half of 2024, and the bank is bullish on the opportunity for this trend to continue in 2025. The bank believes that: 1) In the short term, the recovery of the macro environment and the interest rate cut cycle are expected to drive the overall sector rebound's beta opportunities; 2) Alpha opportunities can be summarized into two main lines: a) outstanding innovative capability while considering the potential for product exports; b) the bearish sentiment has run its course, leading to valuation bottoms and performance reversal, which is the Davis double hit opportunity. The bank points out that 1) innovative drugs going abroad to trade and

Golden Guard Financial NewsNov 27 20:00 ET